BIXT News and Press, Bioxytran Inc From 09/14/23

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its preprint article titled “Evaluation of Complex ...

2023-09-14 08:15:00 ET Summary Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative c...

2023-08-24 10:13:11 ET More on Bioxytran Bioxytran expands institutional investor base with $0.5M equity investment Bioxytran chewable drug for COVID-19 meets phase 2 trial's goals For further details see: Bioxytran gains as FDA clears clinical trial for lead asset

First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it has ...

BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced the initiation of a clinical trial to treat Mild to Moderate COV...

BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that it named Leslie Ajayi, MD as its interim Chief Medical Offi...

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19 BOSTON, MASSACHUSETTS, June ...

2023-06-12 12:51:49 ET Bioxytran ( OTCQB:BIXT ) has entered into a common stock purchase agreement with TRITON FUNDS for $0.5M . The proceeds will help kickstart the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approva...

- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which ...

2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...